Serum Apolipoprotein J in Health, Coronary Heart Disease and Type 2 Diabetes Mellitus
|
Accession number;07A0040471
|
| Title;Serum Apolipoprotein J in Health, Coronary Heart Disease and Type 2 Diabetes Mellitus |
| Author;
KUJIRAOKA TAKESHI
(Department of Advanced Medical Technology and Development, BML Inc.,)
HATTORI HIROAKI
(Department of Advanced Medical Technology and Development, BML Inc.,)
MIWA YOSHIKAZU
(Department of Clinical Pharmacology, Graduate School of Medical Sciences, Kyushu University.)
ISHIHARA MITSUAKI
(Department of Advanced Medical Technology and Development, BML Inc.,)
UENO TAKAHIRO
(The Second Department of Internal Medicine, Nihon University School of Medicine.)
ISHII JUN
(Hokkaido Hospital for Social Insurance.)
TSUJI MASAHIRO
(Hokkaido Health Science University.)
IWASAKI TADAO
(Department of Advanced Medical Technology and Development, BML Inc.,)
SASAGURI YOSHIYUKI
(Department of Clinical Pharmacology, Graduate School of Medical Sciences, Kyushu University.)
FUJIOKA TAKAYUKI
(The Second Department of Internal Medicine, Nihon University School of Medicine.)
SAITO SATOSHI
(The Second Department of Internal Medicine, Nihon University School of Medicine.)
TSUSHIMA MOTOO
(Department of Internal Medicine, Keio University School of Medicine.)
MARUYAMA TARO
(Department of Internal Medicine, Keio University School of Medicine.)
MILLER IRINA P
(Cardiovascular Genetics Div., Univ. of Utah School of Medicine, Salt Lake City, USA, and Oxford ...)
MILLER NORMAN E
(Cardiovascular Genetics Div., Univ. of Utah School of Medicine, Salt Lake City, USA, and Oxford ...)
EGASHIRA TOHRU
(Department of Advanced Medical Technology and Development, BML Inc.,)
|
Journal Title;J Atheroscler Thromb
|
Journal Code:L2187A
|
ISSN:1340-3478
|
|
VOL.13;NO.6;PAGE.314-322 (J-STAGE)(2006)
|
| Figure&Table&Reference;FIG.4, TBL.2, REF.30 |
| Pub. Country;Japan |
| Language;English |
| Abstract;Apolipoprotein (apo) J, clusterin, is ubiquitously expressed in many tissues, and is a component of high-density lipoproteins (HDLs). There is experimental evidence that it may be anti-atherogenic through its effects on cholesterol transport, smooth muscle cell proliferation and lipid peroxidation. HDLs containing apo J and apo A-I carry paraoxonase (PON1), which protects low-density lipoproteins from oxidative modification; however, the extent to which apo J affects coronary heart disease (CHD) is not known. We have developed a sandwich ELISA that enables apo J to be assayed in the range of 13-200 .MU.g/mL. Serum apo J was 52.8.+-.0.8 .MU.g/mL (mean.+-.SEM; range, 36.0-84.3 .MU.g/mL; n=92) in healthy Japanese men, and 49.3.+-.0.5 .MU.g/mL (34.5-72.8; n=241) in healthy Japanese women. Multiple regression of these data and results from 67 men with CHD showed that apo J concentration was unrelated to age, sex or body mass index, but was positively related to serum PON1 (p<0.001) and apo B (p<0.02) concentrations. In women, it was also positively related to blood glucose (p<0.02). After adjusting for its associations with covariates, serum apo J averaged 5.4 .MU.g/mL, lower in CHD men than in controls (p<0.003). Type 2 diabetics had higher apo J concentrations (men, 83.1.+-.3.4 .MU.g/mL, n=64; women, 64.0.+-.2.3 .MU.g/mL, n=46) than healthy men and women (p<0.001). In these Type 2 diabetics, apo J concentration was unrelated to PON1 concentration, but was positively related to blood glucose (p<0.01). After adjustment for its relation to blood glucose, the mean apo J concentration was similar in diabetics and healthy subjects. These findings suggest that apo J may be anti-atherogenic in humans, and that its concentration is raised by Type 2 diabetes. (Author abst.) |
|
|
|
Related Articles;
|
|
|
